サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566753

疼痛管理薬市場：薬剤クラス別、適応症別、疼痛タイプ別：2024～2033年の世界機会分析と産業予測

Pain Management Drugs Market By Drug Class , By Indication By Pain Type : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 216 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
疼痛管理薬市場：薬剤クラス別、適応症別、疼痛タイプ別：2024～2033年の世界機会分析と産業予測
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 216 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

疼痛管理薬市場

疼痛管理薬市場は、2023年に726億米ドルと評価され、2024～2033年にかけてCAGR 4.2%で成長し、2033年には1,096億米ドルに達すると予測されています。

疼痛管理薬は、中程度の不快感から重度の苦痛に至るまで、疼痛を緩和するために処方される薬です。疼痛管理薬の製剤は、オピオイド、抗うつ薬、アセトアミノフェンなどの異なる薬剤クラスで構成されます。これらの薬剤は、筋骨格系、神経障害性、炎症性など様々なタイプの痛みを対象としています。疼痛管理薬の機能に関するメカニズムは、炎症を抑える、神経系における痛みのシグナルを抑制する、痛みの知覚を調節するために脳内化学品を変化させるなど多岐にわたります。

脳卒中、心臓病、II型糖尿病、がんなどの生活習慣病や慢性疾患の増加が疼痛管理薬市場を牽引しています。さらに、投与回数を減らす徐放性製剤など、薬剤の製剤やデリバリー方法の進歩が、患者のコンプライアンスや治療成果を高めるため、薬剤の需要を押し上げています。最近では、ナノ粒子が標的を正確に特定し、低用量で長期的な有効性を提供する能力を有すると予想されることから、ナノ治療の探索が市場で動向しています。

しかし、疼痛管理薬には、心血管イベント、消化管出血、鎮静、腎障害、呼吸抑制などの深刻な副作用があるため、その消費量が制限され、市場拡大の課題となっています。従来の薬剤の危険性を排除するため、副作用がほとんどない可能性のある天然の代替薬が検討されています。例えば、ミトラギナ・スペシオサの木から得られるハーブ物質であるクラトムは、オピオイド薬の代替品として利用されています。クラトムの医薬品は、線維筋痛症や関節炎、神経障害性疼痛などの慢性疼痛を緩和するのに非常に効果的であることが証明されています。

セグメントレビュー

疼痛管理薬市場は、薬剤クラス別、適応症別、疼痛タイプ別、地域別に区分されます。薬剤クラス別では、市場は非ステロイド性抗炎症薬、麻酔薬、抗けいれん薬、抗偏頭痛薬、抗うつ薬、オピオイド、非麻薬性鎮痛薬に分けられます。適応症別では、関節痛、神経障害性疼痛、がん性疼痛、慢性背部痛、術後痛、片頭痛、線維筋痛症、筋挫傷・筋緊張、骨折、急性虫垂炎、その他に分類されます。痛みのタイプ別では、慢性痛と急性痛に二分されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されています。

主要調査結果

薬剤クラス別では、予測期間中、オピオイドセグメントが市場を独占すると予測されます。

適応症別では、術後疼痛セグメントが2033年までに最高株主になると予測されます。

疼痛タイプ別では、慢性疼痛セグメントが予測期間中に市場をリードすると予測されます。

地域別では、北米が2033年までに最も高い収益を上げると予測されています。

本レポートはカスタマイズが可能です。

  • 規制ガイドライン
  • クライアントの関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 疼痛管理薬市場：薬剤クラス別

  • 市場概要
  • 非ステロイド性抗炎症薬
  • 麻酔薬
  • 抗けいれん薬
  • 抗偏頭痛薬
  • 抗うつ薬
  • オピオイド
  • 非麻薬性鎮痛薬

第5章 疼痛管理薬市場：適応症別

  • 市場概要
  • 関節痛
  • 神経障害性疼痛
  • がん性疼痛
  • 慢性腰痛
  • 術後疼痛
  • 片頭痛
  • 線維筋痛症
  • 筋肉の捻挫/挫傷
  • 骨折
  • 急性虫垂炎
  • その他

第6章 疼痛管理薬市場：疼痛タイプ別

  • 市場概要
  • 慢性疼痛
  • 急性痛

第7章 疼痛管理薬市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の疼痛管理薬市場
    • カナダの疼痛管理薬市場
    • メキシコの疼痛管理薬市場
  • 欧州
    • 主要市場動向と機会
    • ドイツの疼痛管理薬市場
    • フランスの疼痛管理薬市場
    • 英国の疼痛管理薬市場
    • イタリアの疼痛管理薬市場
    • スペインの疼痛管理薬市場
    • その他の欧州の疼痛管理薬市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本の疼痛管理薬市場
    • 中国の疼痛管理薬市場
    • インドの疼痛管理薬市場
    • オーストラリアの疼痛管理薬市場
    • 韓国の疼痛管理薬市場
    • その他のアジア太平洋の疼痛管理薬市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの疼痛管理薬市場
    • サウジアラビアの疼痛管理薬市場
    • 南アフリカの疼痛管理薬市場
    • その他のラテンアメリカ・中東・アフリカの疼痛管理薬市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • Novartis AG
  • Eli Lilly And Company
  • Abbott Laboratories
  • Endo Health Solutions, Inc.
  • Purdue Pharma L.P.
  • Pfizer, Inc.
  • Viatris Inc.
  • Merck And Co. Inc.
  • Johnson And Johnson
  • GlaxoSmithKline Plc
目次
Product Code: A00309

Pain Management Drugs Market

The pain management drugs market was valued at $72.6 billion in 2023 and is projected to reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033.

A pain management drug is medication prescribed for the alleviation of pain ranging from moderate discomfort to severe distress. The formulation of pain management drugs comprises of different drug class, including opioids, antidepressants or acetaminophen. These medications target diverse pain types, including musculoskeletal, neuropathic, and inflammatory pain. The mechanisms pertaining to the functioning of pain management drug are diverse such as lowering of inflammation, inhibition of pain signals in the nervous system, or alteration of brain chemistry to modulate the perception of pain.

Increase in the prevalence of lifestyle and chronic diseases such as stroke, heart disease, type II diabetes, and cancer is driving the pain management drugs market. In addition, advancements in drug formulations and delivery methods such as extended-release formulations with reduced dosing frequency are boosting the demand for the drugs as they enhance patient compliance & treatment outcomes. In recent times, explorations in nanotherapeutics are trending in the market as nanoparticles are anticipated to possess the capability of precisely identifying the target and offering long-term efficacy in significantly low dosage.

However, the severe side-effects of pain management drugs; including cardiovascular events, gastrointestinal bleeding, sedation, renal impairment, and respiratory depression; limit their consumption, hence presenting challenges for market expansion. To eliminate the hazards of conventional drugs, natural alternatives are being explored as they have potentially minimal to no side-effects. For instance, Kratom, a herbal substance obtained from the Mitragyna speciosa tree, is being utilized as an alternative to opioid drugs. Kratom medications have proved to be highly effective in providing relief from chronic pain conditions such as fibromyalgia & arthritis and neuropathic pain.

Segment Review

The pain management drugs market is segmented into drug class, indication, pain type, and region. On the basis of drug class, the market is divided into NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. As per indication, it is classified into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, acute appendicitis, and others. By pain type, it is bifurcated into chronic pain and acute pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug class, the opioids segment is expected to dominate the market during the forecast period.

As per indication, the postoperative pain segment is predicted to be the highest shareholder by 2033.

By pain type, the chronic pain segment is anticipated to lead the market during the forecast period.

Region wise, North America is projected to be the highest revenue generator by 2033.

Competition Analysis

The major players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Viatris Inc., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Muscle Sprain/Strain
  • Bone Fracture
  • Acute Appendicitis
  • Others

By Pain Type

  • Chronic Pain
  • Acute Pain

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Novartis AG
    • Eli Lilly & Company
    • Abbott Laboratories
    • Endo Health Solutions, Inc.
    • Purdue Pharma L.P.
    • Pfizer, Inc.
    • Viatris Inc.
    • Merck & Co. Inc.
    • Johnson & Johnson
    • GlaxoSmithKline Plc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Class
  • 4.2. NSAIDs
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Anesthetics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Anticonvulsants
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Anti-migraine Agents
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Antidepressants
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country
  • 4.7. Opioids
    • 4.7.1. Key Market Trends, Growth Factors and Opportunities
    • 4.7.2. Market Size and Forecast, By Region
    • 4.7.3. Market Share Analysis, By Country
  • 4.8. Nonnarcotic Analgesics
    • 4.8.1. Key Market Trends, Growth Factors and Opportunities
    • 4.8.2. Market Size and Forecast, By Region
    • 4.8.3. Market Share Analysis, By Country

CHAPTER 5: PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Arthritic Pain
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Neuropathic Pain
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Cancer Pain
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Chronic Back Pain
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Postoperative Pain
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Migraine
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country
  • 5.8. Fibromyalgia
    • 5.8.1. Key Market Trends, Growth Factors and Opportunities
    • 5.8.2. Market Size and Forecast, By Region
    • 5.8.3. Market Share Analysis, By Country
  • 5.9. Muscle Sprain/Strain
    • 5.9.1. Key Market Trends, Growth Factors and Opportunities
    • 5.9.2. Market Size and Forecast, By Region
    • 5.9.3. Market Share Analysis, By Country
  • 5.10. Bone Fracture
    • 5.10.1. Key Market Trends, Growth Factors and Opportunities
    • 5.10.2. Market Size and Forecast, By Region
    • 5.10.3. Market Share Analysis, By Country
  • 5.11. Acute Appendicitis
    • 5.11.1. Key Market Trends, Growth Factors and Opportunities
    • 5.11.2. Market Size and Forecast, By Region
    • 5.11.3. Market Share Analysis, By Country
  • 5.12. Others
    • 5.12.1. Key Market Trends, Growth Factors and Opportunities
    • 5.12.2. Market Size and Forecast, By Region
    • 5.12.3. Market Share Analysis, By Country

CHAPTER 6: PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Pain Type
  • 6.2. Chronic Pain
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Acute Pain
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: PAIN MANAGEMENT DRUGS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Drug Class
    • 7.2.3. Market Size and Forecast, By Indication
    • 7.2.4. Market Size and Forecast, By Pain Type
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Pain Management Drugs Market
      • 7.2.6.1. Market Size and Forecast, By Drug Class
      • 7.2.6.2. Market Size and Forecast, By Indication
      • 7.2.6.3. Market Size and Forecast, By Pain Type
    • 7.2.7. Canada Pain Management Drugs Market
      • 7.2.7.1. Market Size and Forecast, By Drug Class
      • 7.2.7.2. Market Size and Forecast, By Indication
      • 7.2.7.3. Market Size and Forecast, By Pain Type
    • 7.2.8. Mexico Pain Management Drugs Market
      • 7.2.8.1. Market Size and Forecast, By Drug Class
      • 7.2.8.2. Market Size and Forecast, By Indication
      • 7.2.8.3. Market Size and Forecast, By Pain Type
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Drug Class
    • 7.3.3. Market Size and Forecast, By Indication
    • 7.3.4. Market Size and Forecast, By Pain Type
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Pain Management Drugs Market
      • 7.3.6.1. Market Size and Forecast, By Drug Class
      • 7.3.6.2. Market Size and Forecast, By Indication
      • 7.3.6.3. Market Size and Forecast, By Pain Type
    • 7.3.7. France Pain Management Drugs Market
      • 7.3.7.1. Market Size and Forecast, By Drug Class
      • 7.3.7.2. Market Size and Forecast, By Indication
      • 7.3.7.3. Market Size and Forecast, By Pain Type
    • 7.3.8. UK Pain Management Drugs Market
      • 7.3.8.1. Market Size and Forecast, By Drug Class
      • 7.3.8.2. Market Size and Forecast, By Indication
      • 7.3.8.3. Market Size and Forecast, By Pain Type
    • 7.3.9. Italy Pain Management Drugs Market
      • 7.3.9.1. Market Size and Forecast, By Drug Class
      • 7.3.9.2. Market Size and Forecast, By Indication
      • 7.3.9.3. Market Size and Forecast, By Pain Type
    • 7.3.10. Spain Pain Management Drugs Market
      • 7.3.10.1. Market Size and Forecast, By Drug Class
      • 7.3.10.2. Market Size and Forecast, By Indication
      • 7.3.10.3. Market Size and Forecast, By Pain Type
    • 7.3.11. Rest of Europe Pain Management Drugs Market
      • 7.3.11.1. Market Size and Forecast, By Drug Class
      • 7.3.11.2. Market Size and Forecast, By Indication
      • 7.3.11.3. Market Size and Forecast, By Pain Type
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Drug Class
    • 7.4.3. Market Size and Forecast, By Indication
    • 7.4.4. Market Size and Forecast, By Pain Type
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Pain Management Drugs Market
      • 7.4.6.1. Market Size and Forecast, By Drug Class
      • 7.4.6.2. Market Size and Forecast, By Indication
      • 7.4.6.3. Market Size and Forecast, By Pain Type
    • 7.4.7. China Pain Management Drugs Market
      • 7.4.7.1. Market Size and Forecast, By Drug Class
      • 7.4.7.2. Market Size and Forecast, By Indication
      • 7.4.7.3. Market Size and Forecast, By Pain Type
    • 7.4.8. India Pain Management Drugs Market
      • 7.4.8.1. Market Size and Forecast, By Drug Class
      • 7.4.8.2. Market Size and Forecast, By Indication
      • 7.4.8.3. Market Size and Forecast, By Pain Type
    • 7.4.9. Australia Pain Management Drugs Market
      • 7.4.9.1. Market Size and Forecast, By Drug Class
      • 7.4.9.2. Market Size and Forecast, By Indication
      • 7.4.9.3. Market Size and Forecast, By Pain Type
    • 7.4.10. South Korea Pain Management Drugs Market
      • 7.4.10.1. Market Size and Forecast, By Drug Class
      • 7.4.10.2. Market Size and Forecast, By Indication
      • 7.4.10.3. Market Size and Forecast, By Pain Type
    • 7.4.11. Rest of Asia-Pacific Pain Management Drugs Market
      • 7.4.11.1. Market Size and Forecast, By Drug Class
      • 7.4.11.2. Market Size and Forecast, By Indication
      • 7.4.11.3. Market Size and Forecast, By Pain Type
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Drug Class
    • 7.5.3. Market Size and Forecast, By Indication
    • 7.5.4. Market Size and Forecast, By Pain Type
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Pain Management Drugs Market
      • 7.5.6.1. Market Size and Forecast, By Drug Class
      • 7.5.6.2. Market Size and Forecast, By Indication
      • 7.5.6.3. Market Size and Forecast, By Pain Type
    • 7.5.7. Saudi Arabia Pain Management Drugs Market
      • 7.5.7.1. Market Size and Forecast, By Drug Class
      • 7.5.7.2. Market Size and Forecast, By Indication
      • 7.5.7.3. Market Size and Forecast, By Pain Type
    • 7.5.8. South Africa Pain Management Drugs Market
      • 7.5.8.1. Market Size and Forecast, By Drug Class
      • 7.5.8.2. Market Size and Forecast, By Indication
      • 7.5.8.3. Market Size and Forecast, By Pain Type
    • 7.5.9. Rest of LAMEA Pain Management Drugs Market
      • 7.5.9.1. Market Size and Forecast, By Drug Class
      • 7.5.9.2. Market Size and Forecast, By Indication
      • 7.5.9.3. Market Size and Forecast, By Pain Type

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novartis AG
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Eli Lilly And Company
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Abbott Laboratories
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Endo Health Solutions, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Purdue Pharma L.P.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Pfizer, Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Viatris Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Merck And Co. Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Johnson And Johnson
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. GlaxoSmithKline Plc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments